The use of dostarlimab, a safe and efficient monotherapy in MSI-H rectal cancer patients, an alternative to surgery.

Baz, Yara; Rassam, Maria; Rhayem, Elsa; Zouein, Joseph; Gharios, Joseph; Kourie, Hampig Raphael

Baz, Yara; Rassam, Maria; Rhayem, Elsa; Zouein, Joseph; Gharios, Joseph; Kourie, Hampig Raphael.

Afiliação

Baz Y; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Rassam M; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Rhayem E; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Zouein J; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Gharios J; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Kourie HR; Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

Immunotherapy ; 15(10): 699-701, 2023 07.

Article em En | MEDLINE | ID: mdl-37139962

Assuntos

Anticorpos Monoclonais Humanizados; Neoplasias Retais; Humanos; Neoplasias Retais/terapia

Palavras-chave

Immune checkpoints inhibitors; LARC; MSI-H; dostarlimab; rectal cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Anticorpos Monoclonais Humanizados Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google